

Daily Journal

MAY 20, 2026

TOP INTELLECTUAL PROPERTY LAWYERS 2026

HONORING TOP ATTORNEYS WORKING IN PATENT, TRADEMARK AND COPYRIGHT LAW



JENNIFER SERAPHINE

THOMPSON HINE LLP

SILICON VALLEY

Jennifer Seraphine's path to intellectual property law began with a federal clerkship under Judge Wilkie D. Ferguson, Jr. of the U.S. District Court for the Southern District of Florida — an experience she credits as foundational.

"The clerkship allowed me to first see so clearly how arguments actually come across in real disputes, what makes them work (or fail)," she said. "It's a totally different view from the bench."

Seraphine's recent practice reflects a focus on high-stakes patent litigation, with particular attention to cases involving bad-faith patent assertions. She has represented Canva in two separate suits brought by non-practicing entity DigiMedia Tech in Texas. *DigiMedia Tech, LLC v. Canva Pty Ltd.*, 2:25-cv-00808 (E.D.Tex., filed Aug. 18, 2025).

Rather than absorbing the cost of a nuisance settlement, Seraphine guided Canva in countersuing — first in Washington state, and later in Georgia, where Canva sought a declaratory judgment that DigiMedia violated Georgia's anti-patent troll statute. Both matters settled.

"Wins in cases like these often aren't traditional 'wins,' or dramatic courtroom verdicts — but rather dismissals, a narrowing of the claims, or jurisdictional resolution," Seraphine said. "But they are extremely significant, and effective, as they weaken the patent troll leverage model, reduce potentially massive financial exposure, signal strength and credibility to other plaintiffs, and discourage parallel lawsuits."

Seraphine is also preparing for trial on behalf of Vincent Systems GmbH, a German medical device company whose founder invented technology enabling individually moving fingers in prosthetic hands sized for women and children. The case, pending in the Eastern District of Tennessee, puts Seraphine in the position of defending the inventor's own patents.

In addition, she serves as lead co-counsel for Medtronic in patent litigation against Recor Medical involving renal denervation devices and methods for treating hypertension — a market some analysts value at over \$100 billion. *ReCor Medical, Inc. v. Medtronic Ireland Manufacturing Unlimited Co. et al.*, 3:22-cv-03072 (N.D. Cal., May 25, 2022).

On the broader landscape of patent trolls, she sees no simple fix: "Defending against a single NPE has to be considered in the context of an overall company strategy, because let's face it, it's a whack-a-mole problem if you start feeding the trolls."